Participate in ALS Clinical Trial Today

Open trials

  • The PREVAILS study (PL101-ALS301) is a Phase 3 study using Pridopidine for those with Amyotrophic Lateral Sclerosis. Approximately 500 participants are expected to take part of the study.

    If you are interested in participating, please contact Kevin KMunoz@gpresearchinc.com

  • The COYA ALS study (C302-CLN-2301) is a Phase 2 study using COYA 302 for those with Amyotrophic Lateral Sclerosis. Approximately 120 participants are expected to take part of the study.

    If you are interested in participating, please contact Kevin KMunoz@gpresearchinc.com

  • The Nura Bio. study (NB-4746-201) is a Phase 1b/2 study using NB-4746 for those with Amyotrophic Lateral Sclerosis. Approximately 56 participants are expected to take part of the study.

    If you are interested in participating, please contact Kevin KMunoz@gpresearchinc.com

  • The UNITE-ALS study (USNO.24.002) is a Phase 2 study using Usnoflast for those with Amyotrophic Lateral Sclerosis. Approximately 240 participants are expected to take part of the study.

    For more information, please visit clinicaltrials.gov.

    If you are interested in participating, please contact Kevin KMunoz@gpresearchinc.com

Active but not recruiting trials

  • This clinical trial is now closed for recruitment.

    The ASTRALS Study is a Phase 2 study using VHB937 for those with Amyotrophic Lateral Sclerosis. Approximately 225 participants are expected to take part in North America and Europe.

    For more information, please visit clinicaltrials.gov.

Upcoming trials

If you would like to hear about more about our current or upcoming neurological clinical trials in Montreal please contact us at: info@gengepartners.com

“If we’re not in the beginning for rare disease, we may simply be too late for our patients to get the benefit of these new therapies.”

-Angela Genge

  • Scientists in a laboratory discussing a sample, with microscopes and lab equipment around them.

    Our mission

    To improve patient health and well-being by conducting cutting-edge clinical research. We strive to foster a culture of innovation, collaboration, and excellence in all aspects of our research, and to contribute to the global effort to improve healthcare for all.

  • Three scientists or medical professionals wearing lab coats, masks, goggles, and haircovers working together at a computer in a laboratory setting.

    Our vision

    To be a leading force in advancing medical knowledge and improving patient care through innovative and ethical clinical research

  • Female scientist in a lab coat holds a clipboard in a laboratory with glass walls and scientific equipment.

    Our future

    GP Research will continue to be at the forefront of clinical research, utilizing the latest technologies and methodologies to bring new treatments and therapies to patients in need. Our commitment to patient safety, scientific rigor, and ethical conduct will remain steadfast, as we work to improve healthcare for all and make a lasting impact on the field of medicine.

Our facility:

GP Research @ Glen
5100 Boul. de Maisonneuve Ouest, 6th floor
Montreal, QC H4A 3TA